Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) VP Ken Moseley sold 2,200 shares of the business’s stock in a transaction on Tuesday, September 20th. The shares were sold at an average price of $20.01, for a total transaction of $44,022.00. Following the sale, the vice president now directly owns 1,044 shares of the company’s stock, valued at approximately $20,890.44. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Ken Moseley also recently made the following trade(s):

  • On Monday, August 15th, Ken Moseley sold 1,000 shares of Bellicum Pharmacueticals stock. The shares were sold at an average price of $20.00, for a total transaction of $20,000.00.

Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) opened at 19.65 on Thursday. The company has a 50-day moving average of $18.36 and a 200 day moving average of $13.19. Bellicum Pharmacueticals Inc. has a one year low of $7.24 and a one year high of $23.84. The company’s market cap is $531.49 million.

Bellicum Pharmacueticals (NASDAQ:BLCM) last posted its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.57) by $0.04. Bellicum Pharmacueticals had a negative return on equity of 42.22% and a negative net margin of 21,774.65%. During the same quarter in the previous year, the firm posted ($0.40) earnings per share. Analysts anticipate that Bellicum Pharmacueticals Inc. will post ($2.34) earnings per share for the current year.

A number of brokerages have recently issued reports on BLCM. Piper Jaffray Cos. reissued a “buy” rating on shares of Bellicum Pharmacueticals in a research report on Saturday, July 9th. Jefferies Group reissued a “buy” rating on shares of Bellicum Pharmacueticals in a research report on Tuesday, August 23rd. Zacks Investment Research raised shares of Bellicum Pharmacueticals from a “sell” rating to a “hold” rating in a research report on Monday, July 11th. SunTrust Banks Inc. began coverage on shares of Bellicum Pharmacueticals in a research report on Thursday, June 2nd. They set a “buy” rating and a $20.00 price objective for the company. Finally, Citigroup Inc. raised shares of Bellicum Pharmacueticals from a “neutral” rating to a “buy” rating and set a $24.00 price objective for the company in a research report on Tuesday, August 9th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $24.25.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. ProShare Advisors LLC boosted its position in Bellicum Pharmacueticals by 10.6% in the second quarter. ProShare Advisors LLC now owns 22,654 shares of the biopharmaceutical company’s stock worth $294,000 after buying an additional 2,163 shares in the last quarter. Geode Capital Management LLC boosted its position in Bellicum Pharmacueticals by 4.0% in the first quarter. Geode Capital Management LLC now owns 64,665 shares of the biopharmaceutical company’s stock worth $604,000 after buying an additional 2,513 shares in the last quarter. BlackRock Group LTD boosted its position in Bellicum Pharmacueticals by 27.9% in the first quarter. BlackRock Group LTD now owns 12,443 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 2,713 shares in the last quarter. Alliancebernstein L.P. boosted its position in Bellicum Pharmacueticals by 24.4% in the second quarter. Alliancebernstein L.P. now owns 19,400 shares of the biopharmaceutical company’s stock worth $251,000 after buying an additional 3,800 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Bellicum Pharmacueticals by 3.9% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 104,509 shares of the biopharmaceutical company’s stock worth $1,354,000 after buying an additional 3,888 shares in the last quarter. 65.24% of the stock is owned by institutional investors and hedge funds.

Bellicum Pharmacueticals Company Profile

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

5 Day Chart for NASDAQ:BLCM

Receive News & Ratings for Bellicum Pharmacueticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmacueticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.